Zh. A. Valeeva

ORCID: 0000-0001-8567-2671
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Pediatric health and respiratory diseases
  • Asthma and respiratory diseases
  • Respiratory and Cough-Related Research
  • Respiratory viral infections research
  • Foreign Language Teaching Methods
  • Medical and Biological Sciences
  • Infant Health and Development
  • Healthcare Systems and Public Health
  • Child and Adolescent Health
  • Allergic Rhinitis and Sensitization

Bashkir State Medical University
2024

Introduction. Cough is the most common manifestation of respiratory infections affecting upper and lower airways, indicating impaired mucociliary clearance. Mucolytic agents are often used to normalize patient's condition improve mucus To clearance, mucolytic used. Considering action hypertonic solutions, we conducted a comparative clinical study evaluate efficacy safety combination 3% saline solution high molecular weight hyaluronic acid 0.01% (Ingasalin® 3%) in treatment acute bronchitis...

10.31146/2949-4664-apps-2-1-79-87 article EN cc-by Archives of Pediatrics and Pediatric Surgery 2024-03-26

Введение. Лечение острых респираторных вирусных инфекций, особенно в период эпидемических подъемов, – первоочередная задача для педиатров и врачей других специальностей. После пандемии новой коронавирусной инфекции COVID-19 назрела необходимость оценки эффективности безопасности индуктора интерферона ввиду произошедших изменений циркуляции вирусов. Цель работы. Оценить эффективность комплексной терапии инфекций у детей 3-18 лет сравнении со стандартной терапией условиях рутинной...

10.51793/os.2024.27.12.010 article RU cc-by-nc-nd Лечащий врач 2024-12-23

Аллергология/Иммунология Оригинальные статьиКлиническая эффективность базисной противовоспалительной терапии аллергического ринита у детей Р.М.Файзуллина 1 , З.А.Шангареева А.В.Санникова Ж.А

10.32364/2587-6821-2020-4-1-15-18 article RU cc-by Russian Medical Inquiry 2020-01-01

Objective: to evaluate the clinical efficacy of targeted therapy with omalizumab in children moderate severe uncontrolled bronchial asthma. Materials and methods: 7 receiving a hospital polyclinic Ufa City Children’s Clinical Hospital No. 17 were under observation. In accordance instructions for use, monoclonal antibody drug was administered subcutaneously every 2-4 weeks. The dosage determined based on child’s body weight initial level serum IgE. anamnesis life disease, results instrumental...

10.21886/2219-8075-2022-13-2-134-140 article EN cc-by Medical Herald of the South of Russia 2022-06-15
Coming Soon ...